Sun Pharma Q2 Results 2023

Read this story to learn about Q2- highlights, performance, earnings, dividend updates, market performance, etc.,

Highlights of the Result

· The Gross sales for Q2 FY’24 stood at ₹ 120,031 Mn · Net profit for Q2 FY’24 stood at ₹ 23,755 Mn · EBITDA is at ₹ 31,794 Mn, up by 7.5% YoY

Performance Highlights

· The Gross sales grew 11% YoY · Profit after tax (PAT) saw an increment of 5% YoY · R&D investment stands at       ₹ 7,734 Mn, representing 6.4% of sales

Domestic Formulations

Sun Pharma's Q2FY24 India sales stood at Rs. 38,425M, up 11.1% YoY; No. 1 in market share and prescriptions, introduced 8 new products in Q2FY24

Emerging Markets Formulation

Sun Pharma's Q2FY24 sales stood at US$ 284M, with 9.4% YoY growth, and 19.5% of total sales. H1FY24 sales: US$ 545M, up 8% YoY.